Idiopathic Retroperitoneal Fibrosis: Long-term Risk and Predictors of Relapse.

Abstract

RATIONALE & OBJECTIVE\nIdiopathic retroperitoneal fibrosis (IRF) is a rare disorder of unknown cause. Medical therapy can induce remission, but disease relapses are common. This study sought to characterize long-term outcomes of IRF and the factors associated with disease recurrences.\n\n\nSTUDY DESIGN\nRetrospective cohort study.\n\n\nSETTING & PARTICIPANTS\nRetrospective analysis of 50 patients with IRF prospectively followed up for 8.9 (IQR, 4.7-12.7) years at a tertiary-care referral center.\n\n\nEXPOSURES\nDemographic, clinical, treatment, and laboratory parameters, including measures of autoimmunity.\n\n\nOUTCOME\nDisease relapse.\n\n\nANALYTICAL APPROACH\nProportional hazards analysis for the subdistribution of competing risks.\n\n\nRESULTS\n49 patients received medical treatment and 35 underwent interventional procedures. All patients experienced a clinical response (defined as regression of disease-related symptoms and hydronephrosis, and decrease in the maximal transverse diameter of the retroperitoneal mass on computed tomography of >50%), 44 of whom responded within 1 year. The remaining 6 responded over a median of 2.95 years after starting therapy. 40 patients were alive at last observation, 1 receiving maintenance dialysis and 15 with estimated glomerular filtration rate\xa0< 60mL/min/1.73m2. Patient survival at 5, 10, and 15 years was 95%, 84%, and 68%, respectively. 19 (38%) patients had at least 1 relapse (occurring a median of 5.19 years after starting therapy), defined as an increase in serum creatinine level of at least 30% or recurrence/development of hydronephrosis and\xa0≥20% increase in the maximal transverse diameter of the retroperitoneal mass on computed tomography. Cumulative incidences of relapse at 5, 10, and 15 years were 21%, 41%, and 48%, respectively. Baseline antinuclear antibody positivity and male sex were associated with relapse (subdistribution hazard ratios [sHRs] of 5.35 [95% CI, 2.15-13.27] and 4.94 [95% CI, 1.32-18.57], respectively), while higher corticosteroid therapy dosage at 1 year (sHR for relapse per 1-mg/d greater dosage, 0.91 [95% CI, 0.84-0.98]) and treatment with prednisone alone or with tamoxifen (sHR for relapse of 0.25 [95% CI, 0.07-0.85] vs other therapies) were associated with lower rate of relapse.\n\n\nLIMITATIONS\nSmall sample size and variable approaches to therapy.\n\n\nCONCLUSIONS\nIRF relapses were common and\xa0were experienced more frequently by male patients. Corticosteroids alone or with tamoxifen were associated with a lower rate of relapse. The\xa0strong association of antinuclear antibody positivity with relapse supports the hypothesis of an autoimmune pathogenesis of\xa0IRF.